Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Подагра: от Гиппократа до наших дней
Подагра: от Гиппократа до наших дней
Гуляев С.В., Чеботарева Н.В., Моисеев С.В. Подагра: от Гиппократа до наших дней. Терапевтический архив. 2022;94(12):1438–1441. DOI: 10.26442/00403660.2022.12.201997
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Подагра – одно из наиболее древних заболеваний суставов, точные причины и механизмы развития которого расшифрованы только в последнее столетие. В историческом очерке отражены основные этапы развития научных представлений о подагре, ее причинах и методах лечения. Приведены различные теории патогенеза болезни, начиная со времен Гиппократа и заканчивая сегодняшним днем. Представлены результаты современных исследований, посвященных генетическим и эпидемиологическим аспектам болезни.
Ключевые слова: подагра, гиперурикемия, исторический обзор, мочевая кислота, пурины
Keywords: gout, podagra, hyperuricemia, historical review, uric acid, purines
Ключевые слова: подагра, гиперурикемия, исторический обзор, мочевая кислота, пурины
________________________________________________
Keywords: gout, podagra, hyperuricemia, historical review, uric acid, purines
Полный текст
Список литературы
1. MacKenzie CR. Gout and Hyperuricemia: an Historical Perspective. Curr Treat Options in Rheum. 2015;1:119-30. DOI:10.1007/s40674-015-0012-9
2. Kittredge WE, Downs R. The role of gout in the formation of urinary calculi. J Urol. 1952;67(6):841-9. DOI:10.1016/s0022-5347(17)68427-1
3. Nuki G, Simkin PA. Concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(1):S1. DOI:10.1186/ar1906
4. Omole OB. The evolution of gout (an old lifestyle disease). South African Family Practice. 2009;51(5):396-8. DOI:10.1080/20786204.2009.10873890
5. Некрасов Н.А. Полное собрание сочинений и писем в пятнадцати томах. Художественные произведения: в 15 т. Т. 5. Кому на Руси жить хорошо. Л.: Наука, 1982; c. 55 [Nekrasov NA. Polnoie sobraniie sochinenii i pisem v piatnadtsati tomakh. Khudozhestvennyie proizvedeniia: v 15 t. T. 5. Komu na Rusi zhit' khorosho. Leningrad: Nauka, 1982; p. 55 (in Russian)].
6. McCarty DJ. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum. 1970;13(4):414-8. DOI:10.1002/art.1780130408
7. Sydenham T. A treatise of the gout and dropsy. London: GGJ, J Robinson. W Otridge, S Hayes and E Newbery, 1683.
8. Scheele KW. Exam enchemicum calculi urinari. Opuscula. 1776;2:73.
9. Fourcroy AF. Systême des connaisances chimiques, et leurs applications aux phénomenes de la nature et de l’art. Paris: Baudoin, 1800.
10. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly, 1859.
11. Fischer E. Untersuchungen in der Puringruppe. Berlin: Springer, 1907.
12. Mccarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60. DOI:10.7326/0003-4819-54-3-452
13. Seegmiller JE, Howell RR, Malawista RE. Inflammatory reaction to sodium urate. Its possible relationship to genesis of acute gouty arthritis. JAMA. 1962;180(6):469-75. DOI:10.1001/jama.1962.03050190031006
14. Marson P, Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. 2012;63(4):199-206. DOI:10.4081/reumatismo.2011.199
15. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11(1):71-5. DOI:10.1093/ije/11.1.71
16. Hayward RA, Rathod T, Roddy E, et al. The association of gout with socioeconomic status in primary care: a cross-sectional observational study. Rheumatology. 2013;52(11):2004-8. DOI:10.1093/rheumatology/ket262
17. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med. 1970;73(3):359-66.
DOI:10.7326/0003-4819-73-3-359
18. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. DOI:10.1038/nrrheum.2015.91
19. Chen-Xu M, Yokose C, Rai SK, Pillinger MH. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991-9. DOI:10.1002/art.40807
20. Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet. 1967;2(7515):528-31. DOI:10.1016/s0140-6736(67)90494-1
21. Keenan RT, Krasnokutsky S, Pillinger MH. Etiology and Pathogenesis of Hyperuricemia and Gout. In: Firestein GS, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley & Firestein's textbook of rheumatology. Tenth ed. Philadelphia, PA: Elsevier, 2017; p. 1608-9.
22. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679-87.e1. DOI:10.1016/j.amjmed.2011.09.033
23. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
24. Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways in fluencing human serum urate levels. Nat Genet. 2019;51(10):1459-74. DOI:10.1038/s41588-019-0504-x
25. Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 2005;54(11):1435-41. DOI:10.1016/j.metabol.2005.05.007
26. Punzi L, Scanu A, Ramonda R, Oliviero F. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev. 2012;12(1):66-71. DOI:10.1016/j.autrev.2012.07.024
27. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric Acid and Cardiovascular Disease: An Update. Eur Cardiol. 2016;11(1):54-9. DOI:10.15420/ecr.2016:4:2
28. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339
29. Kippen I, Whitehouse MW, Klinenberg JR. Pharmacology of uricosuric drugs. Ann Rheum Dis. 1974;33(4):391-6. DOI:10.1136/ard.33.4.391
30. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82. DOI:10.3899/jrheum.080814
31. Чикина М.Н., Елисеев М.С., Желябина О.В. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020;14(2):97-103 [Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaia revmatologiia. 2020;14(2):97-103 (in Russian)]. DOI:10.14412/1996-7012-2020-2-97-103
32. Елисеев М.С., Желябина О.В., Мукагова М.В., Насонов Е.Л. Клинический опыт применения блокатора интерлейкина 1β канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22 [Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin 1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopuninol is used. Sovremennaia revmatologiia. 2015;9(2):16-22 (in Russian)]. DOI:10.14412/1996-7012-2015-2-16-22
33. Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3S):S31-8. DOI:10.1016/j.semarthrit.2020.04.011
2. Kittredge WE, Downs R. The role of gout in the formation of urinary calculi. J Urol. 1952;67(6):841-9. DOI:10.1016/s0022-5347(17)68427-1
3. Nuki G, Simkin PA. Concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(1):S1. DOI:10.1186/ar1906
4. Omole OB. The evolution of gout (an old lifestyle disease). South African Family Practice. 2009;51(5):396-8. DOI:10.1080/20786204.2009.10873890
5. Nekrasov NA. Polnoie sobraniie sochinenii i pisem v piatnadtsati tomakh. Khudozhestvennyie proizvedeniia: v 15 t. T. 5. Komu na Rusi zhit' khorosho. Leningrad: Nauka, 1982; p. 55 (in Russian).
6. McCarty DJ. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum. 1970;13(4):414-8. DOI:10.1002/art.1780130408
7. Sydenham T. A treatise of the gout and dropsy. London: GGJ, J Robinson. W Otridge, S Hayes and E Newbery, 1683.
8. Scheele KW. Exam enchemicum calculi urinari. Opuscula. 1776;2:73.
9. Fourcroy AF. Systême des connaisances chimiques, et leurs applications aux phénomenes de la nature et de l’art. Paris: Baudoin, 1800.
10. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly, 1859.
11. Fischer E. Untersuchungen in der Puringruppe. Berlin: Springer, 1907.
12. Mccarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60. DOI:10.7326/0003-4819-54-3-452
13. Seegmiller JE, Howell RR, Malawista RE. Inflammatory reaction to sodium urate. Its possible relationship to genesis of acute gouty arthritis. JAMA. 1962;180(6):469-75. DOI:10.1001/jama.1962.03050190031006
14. Marson P, Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. 2012;63(4):199-206. DOI:10.4081/reumatismo.2011.199
15. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11(1):71-5. DOI:10.1093/ije/11.1.71
16. Hayward RA, Rathod T, Roddy E, et al. The association of gout with socioeconomic status in primary care: a cross-sectional observational study. Rheumatology. 2013;52(11):2004-8. DOI:10.1093/rheumatology/ket262
17. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med. 1970;73(3):359-66.
DOI:10.7326/0003-4819-73-3-359
18. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. DOI:10.1038/nrrheum.2015.91
19. Chen-Xu M, Yokose C, Rai SK, Pillinger MH. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991-9. DOI:10.1002/art.40807
20. Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet. 1967;2(7515):528-31. DOI:10.1016/s0140-6736(67)90494-1
21. Keenan RT, Krasnokutsky S, Pillinger MH. Etiology and Pathogenesis of Hyperuricemia and Gout. In: Firestein GS, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley & Firestein's textbook of rheumatology. Tenth ed. Philadelphia, PA: Elsevier, 2017; p. 1608-9.
22. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679-87.e1. DOI:10.1016/j.amjmed.2011.09.033
23. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
24. Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways in fluencing human serum urate levels. Nat Genet. 2019;51(10):1459-74. DOI:10.1038/s41588-019-0504-x
25. Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 2005;54(11):1435-41. DOI:10.1016/j.metabol.2005.05.007
26. Punzi L, Scanu A, Ramonda R, Oliviero F. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev. 2012;12(1):66-71. DOI:10.1016/j.autrev.2012.07.024
27. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric Acid and Cardiovascular Disease: An Update. Eur Cardiol. 2016;11(1):54-9. DOI:10.15420/ecr.2016:4:2
28. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339
29. Kippen I, Whitehouse MW, Klinenberg JR. Pharmacology of uricosuric drugs. Ann Rheum Dis. 1974;33(4):391-6. DOI:10.1136/ard.33.4.391
30. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82. DOI:10.3899/jrheum.080814
31. Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaia revmatologiia. 2020;14(2):97-103 (in Russian). DOI:10.14412/1996-7012-2020-2-97-103
32. Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin 1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopuninol is used. Sovremennaia revmatologiia. 2015;9(2):16-22 (in Russian). DOI:10.14412/1996-7012-2015-2-16-22
33. Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3S):S31-8. DOI:10.1016/j.semarthrit.2020.04.011
2. Kittredge WE, Downs R. The role of gout in the formation of urinary calculi. J Urol. 1952;67(6):841-9. DOI:10.1016/s0022-5347(17)68427-1
3. Nuki G, Simkin PA. Concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(1):S1. DOI:10.1186/ar1906
4. Omole OB. The evolution of gout (an old lifestyle disease). South African Family Practice. 2009;51(5):396-8. DOI:10.1080/20786204.2009.10873890
5. Некрасов Н.А. Полное собрание сочинений и писем в пятнадцати томах. Художественные произведения: в 15 т. Т. 5. Кому на Руси жить хорошо. Л.: Наука, 1982; c. 55 [Nekrasov NA. Polnoie sobraniie sochinenii i pisem v piatnadtsati tomakh. Khudozhestvennyie proizvedeniia: v 15 t. T. 5. Komu na Rusi zhit' khorosho. Leningrad: Nauka, 1982; p. 55 (in Russian)].
6. McCarty DJ. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum. 1970;13(4):414-8. DOI:10.1002/art.1780130408
7. Sydenham T. A treatise of the gout and dropsy. London: GGJ, J Robinson. W Otridge, S Hayes and E Newbery, 1683.
8. Scheele KW. Exam enchemicum calculi urinari. Opuscula. 1776;2:73.
9. Fourcroy AF. Systême des connaisances chimiques, et leurs applications aux phénomenes de la nature et de l’art. Paris: Baudoin, 1800.
10. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly, 1859.
11. Fischer E. Untersuchungen in der Puringruppe. Berlin: Springer, 1907.
12. Mccarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60. DOI:10.7326/0003-4819-54-3-452
13. Seegmiller JE, Howell RR, Malawista RE. Inflammatory reaction to sodium urate. Its possible relationship to genesis of acute gouty arthritis. JAMA. 1962;180(6):469-75. DOI:10.1001/jama.1962.03050190031006
14. Marson P, Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. 2012;63(4):199-206. DOI:10.4081/reumatismo.2011.199
15. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11(1):71-5. DOI:10.1093/ije/11.1.71
16. Hayward RA, Rathod T, Roddy E, et al. The association of gout with socioeconomic status in primary care: a cross-sectional observational study. Rheumatology. 2013;52(11):2004-8. DOI:10.1093/rheumatology/ket262
17. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med. 1970;73(3):359-66.
DOI:10.7326/0003-4819-73-3-359
18. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. DOI:10.1038/nrrheum.2015.91
19. Chen-Xu M, Yokose C, Rai SK, Pillinger MH. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991-9. DOI:10.1002/art.40807
20. Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet. 1967;2(7515):528-31. DOI:10.1016/s0140-6736(67)90494-1
21. Keenan RT, Krasnokutsky S, Pillinger MH. Etiology and Pathogenesis of Hyperuricemia and Gout. In: Firestein GS, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley & Firestein's textbook of rheumatology. Tenth ed. Philadelphia, PA: Elsevier, 2017; p. 1608-9.
22. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679-87.e1. DOI:10.1016/j.amjmed.2011.09.033
23. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
24. Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways in fluencing human serum urate levels. Nat Genet. 2019;51(10):1459-74. DOI:10.1038/s41588-019-0504-x
25. Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 2005;54(11):1435-41. DOI:10.1016/j.metabol.2005.05.007
26. Punzi L, Scanu A, Ramonda R, Oliviero F. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev. 2012;12(1):66-71. DOI:10.1016/j.autrev.2012.07.024
27. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric Acid and Cardiovascular Disease: An Update. Eur Cardiol. 2016;11(1):54-9. DOI:10.15420/ecr.2016:4:2
28. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339
29. Kippen I, Whitehouse MW, Klinenberg JR. Pharmacology of uricosuric drugs. Ann Rheum Dis. 1974;33(4):391-6. DOI:10.1136/ard.33.4.391
30. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82. DOI:10.3899/jrheum.080814
31. Чикина М.Н., Елисеев М.С., Желябина О.В. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020;14(2):97-103 [Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaia revmatologiia. 2020;14(2):97-103 (in Russian)]. DOI:10.14412/1996-7012-2020-2-97-103
32. Елисеев М.С., Желябина О.В., Мукагова М.В., Насонов Е.Л. Клинический опыт применения блокатора интерлейкина 1β канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22 [Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin 1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopuninol is used. Sovremennaia revmatologiia. 2015;9(2):16-22 (in Russian)]. DOI:10.14412/1996-7012-2015-2-16-22
33. Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3S):S31-8. DOI:10.1016/j.semarthrit.2020.04.011
________________________________________________
2. Kittredge WE, Downs R. The role of gout in the formation of urinary calculi. J Urol. 1952;67(6):841-9. DOI:10.1016/s0022-5347(17)68427-1
3. Nuki G, Simkin PA. Concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(1):S1. DOI:10.1186/ar1906
4. Omole OB. The evolution of gout (an old lifestyle disease). South African Family Practice. 2009;51(5):396-8. DOI:10.1080/20786204.2009.10873890
5. Nekrasov NA. Polnoie sobraniie sochinenii i pisem v piatnadtsati tomakh. Khudozhestvennyie proizvedeniia: v 15 t. T. 5. Komu na Rusi zhit' khorosho. Leningrad: Nauka, 1982; p. 55 (in Russian).
6. McCarty DJ. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum. 1970;13(4):414-8. DOI:10.1002/art.1780130408
7. Sydenham T. A treatise of the gout and dropsy. London: GGJ, J Robinson. W Otridge, S Hayes and E Newbery, 1683.
8. Scheele KW. Exam enchemicum calculi urinari. Opuscula. 1776;2:73.
9. Fourcroy AF. Systême des connaisances chimiques, et leurs applications aux phénomenes de la nature et de l’art. Paris: Baudoin, 1800.
10. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly, 1859.
11. Fischer E. Untersuchungen in der Puringruppe. Berlin: Springer, 1907.
12. Mccarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60. DOI:10.7326/0003-4819-54-3-452
13. Seegmiller JE, Howell RR, Malawista RE. Inflammatory reaction to sodium urate. Its possible relationship to genesis of acute gouty arthritis. JAMA. 1962;180(6):469-75. DOI:10.1001/jama.1962.03050190031006
14. Marson P, Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. 2012;63(4):199-206. DOI:10.4081/reumatismo.2011.199
15. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11(1):71-5. DOI:10.1093/ije/11.1.71
16. Hayward RA, Rathod T, Roddy E, et al. The association of gout with socioeconomic status in primary care: a cross-sectional observational study. Rheumatology. 2013;52(11):2004-8. DOI:10.1093/rheumatology/ket262
17. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH. Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med. 1970;73(3):359-66.
DOI:10.7326/0003-4819-73-3-359
18. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. DOI:10.1038/nrrheum.2015.91
19. Chen-Xu M, Yokose C, Rai SK, Pillinger MH. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991-9. DOI:10.1002/art.40807
20. Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet. 1967;2(7515):528-31. DOI:10.1016/s0140-6736(67)90494-1
21. Keenan RT, Krasnokutsky S, Pillinger MH. Etiology and Pathogenesis of Hyperuricemia and Gout. In: Firestein GS, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley & Firestein's textbook of rheumatology. Tenth ed. Philadelphia, PA: Elsevier, 2017; p. 1608-9.
22. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679-87.e1. DOI:10.1016/j.amjmed.2011.09.033
23. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
24. Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways in fluencing human serum urate levels. Nat Genet. 2019;51(10):1459-74. DOI:10.1038/s41588-019-0504-x
25. Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 2005;54(11):1435-41. DOI:10.1016/j.metabol.2005.05.007
26. Punzi L, Scanu A, Ramonda R, Oliviero F. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev. 2012;12(1):66-71. DOI:10.1016/j.autrev.2012.07.024
27. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric Acid and Cardiovascular Disease: An Update. Eur Cardiol. 2016;11(1):54-9. DOI:10.15420/ecr.2016:4:2
28. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339
29. Kippen I, Whitehouse MW, Klinenberg JR. Pharmacology of uricosuric drugs. Ann Rheum Dis. 1974;33(4):391-6. DOI:10.1136/ard.33.4.391
30. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82. DOI:10.3899/jrheum.080814
31. Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaia revmatologiia. 2020;14(2):97-103 (in Russian). DOI:10.14412/1996-7012-2020-2-97-103
32. Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin 1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopuninol is used. Sovremennaia revmatologiia. 2015;9(2):16-22 (in Russian). DOI:10.14412/1996-7012-2015-2-16-22
33. Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3S):S31-8. DOI:10.1016/j.semarthrit.2020.04.011
Авторы
С.В. Гуляев*, Н.В. Чеботарева, С.В. Моисеев
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*guldoc@mail.ru
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*guldoc@mail.ru
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*guldoc@mail.ru
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*guldoc@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.